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OBJECTIVES We sought to demonstrate non-angiotensin converting enzyme (ACE) dependent angioten-
sin II (AII) generating pathways in resistance arteries from patients with chronic heart failure
(CHF).
BACKGROUND Non-ACE dependent AII generation occurs in resistance arteries from normal volunteers.
Inhibition of non-ACE dependent AII generation may have therapeutic potential in CHF.
METHODS Resistance arteries were dissected from gluteal biopsies from patients with coronary heart
disease (CHD) and preserved left ventricular function and from patients with CHF. Using
wire myography, concentration response curves to angiotensin I (AI) and AII were
constructed in the presence of 1) vehicle, 2) chymostatin [an inhibitor of chymase], 3)
enalaprilat, and 4) the combination of chymostatin and enalaprilat.
RESULTS In resistance arteries from patients with CHD, the vasoconstrictor response to AI was not
inhibited by either inhibitor alone (chymostatin [p $ 0.05] or enalaprilat [p $ 0.05]) but was
significantly inhibited by the combination (p , 0.001). In arteries from patients with CHF,
AI responses were inhibited by enalaprilat (p , 0.05) but not by chymostatin alone (p .
0.05). The combination of chymostatin and enalaprilat markedly inhibited the response to AI
(p , 0.001) to a greater degree than enalaprilat alone (p # 0.01).
CONCLUSIONS Non-ACE dependent AII generating pathways exist in resistance arteries from patients with
both CHF and CHD. In resistance arteries from patients with CHD, inhibition of either the
ACE or chymase pathway alone has no effect on AII generation, and both pathways must be
blocked before the vasoconstrictor action of AI is inhibited. In CHF, blockade of ACE results
in marked inhibition of responses to AI, but this is enhanced by coinhibition of chymase.
These studies suggest that full suppression of the renin-angiotensin system cannot be
achieved by ACE inhibition alone and provide a rationale for developing future therapeutic
strategies. (J Am Coll Cardiol 2001;37:1056–61) © 2001 by the American College of
Cardiology
The traditional view that angiotensin II (AII) formation is
solely dependent on angiotensin converting enzyme (ACE)
has recently been challenged. Non-ACE dependent conver-
sion of angiotensin I (AI) to AII has been demonstrated in
homogenates of human myocardial tissue (1,2). In vitro,
non-ACE dependent conversion of AI to AII is brought
about by one or more serine proteases. The most important
of these is thought to be chymase (3,4) as non-ACE
mediated AII formation is substantially blocked by chymase
inhibitors such as chymostatin (2). That these non-ACE
pathways are functionally important in human blood vessels
has recently been demonstrated by Voors et al. (5) in large
arteries and by our group in small resistance arteries from
normal human volunteers (6).
Demonstration of this dual pathway for AII generation
has important potential implications for the treatment of a
number of cardiovascular diseases, especially chronic heart
failure (CHF). Blockade of the renin-angiotensin-
aldosterone system (RAAS) improves symptoms and sur-
vival in heart failure (7,8), and greater inhibition brings
about greater benefit (9). The current approach to RAAS
interruption is ACE inhibition. However, the existence of a
dual pathway means that that AII generation might persist
in CHF, despite ACE inhibition, and raises the possibility
that either the syndrome itself, or ACE inhibition, might
also up-regulate the alternative pathway. It is known that
treatment of CHF with an ACE inhibitor does not result in
long-term suppression of AII plasma levels (10). Further-
more, in one study of patients with CHF, deterioration in
left ventricular (LV) function occurred despite ACE inhi-
bition, and this was associated with plasma concentrations
of AII that not only failed to show suppression but were
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elevated compared with those found in age and gender-
matched controls without CHF (11).
The objective of this study was to determine whether or
not non-ACE dependent AI to AII conversion occurs in the
resistance arteries of patients with CHF who receive long-
term treatment with ACE inhibitors. We also studied
whether or not non-ACE dependent AII generation occurs
in resistance arteries from patients with coronary heart
disease (CHD) and preserved ventricular function who have
not been treated with ACE inhibitors.
METHODS
Patients. All patients with renal failure (creatinine .200
mmol/l) and diabetes mellitus were excluded. Written in-
formed consent was obtained from each patient, and all
protocols were approved by the local committee on medical
ethics.
Patients with CHF. Ambulatory patients with New York
Heart Association class II/III CHF were studied. All were
on long-term (.3 months) ACE inhibitor and diuretic
treatment. The etiology of CHF was CHD in all cases, and
each patient had an echocardiographic LV ejection fraction
(LVEF) ,40% (Simpson’s biplane method). All patients
had suffered a previous myocardial infarction. The patient’s
usual medication (including ACE inhibitor therapy) was
taken on the study morning. These patients underwent
gluteal biopsy and study of subcutaneous resistance arteries.
Patients with CHD. Patients with chronic stable angina
attending outpatient clinics were studied. All patients had
preserved LV systolic function, determined as an echocar-
diographic LVEF $40% (Simpson’s biplane method), and
none was treated with an ACE inhibitor. Patients under-
went gluteal biopsy and study of subcutaneous resistance
arteries.
Materials. Human AI, AII, bradykinin (BK), norepineph-
rine (NE) and acetylcholine (ACh) were purchased from
Sigma (Poole, United Kingdom). Chymostatin was pur-
chased from Bachem (Safron-Walden, United Kingdom),
and enalaprilat was a gift from Merck, Sharp and Dohme
Ltd. The studies were performed on a Mulvany-Halpern
four-channel wire myograph (J.P. Trading, Aarhus, Den-
mark).
Experimental protocol. BLOOD SAMPLING, BIOPSY PROCE-
DURE AND ARTERY PREPARATION. After 15 min supine
rest, blood was drawn from a cannula in an antecubital vein
for estimation of blood chemistry and serum cholesterol.
Subcutaneous gluteal biopsies were then obtained from each
patient under local anesthesia (1% lidocaine) by the method
previously described (12). Dissected tissue was placed im-
mediately into cold 0.9% NaCl and then transferred to cold
Kreb’s solution (composition in mM: NaCl 118.4, KCl 4.7,
MgSO4.H2O 1.2, KH2PO4 1.2. Na HCO3 24.9, CaCl2
2.5, glucose 11.1, EDTA 0.023, which gives a pH of 7.4
when gassed with a 5% CO2/95% O2 mixture). Where
possible, four resistance arteries approximately 2 mm in
length were dissected free of fat. Dissected arteries were
stored in Kreb’s solution overnight at 4°C. Approximately
24 h after the biopsy they were mounted on two 40 mm
diameter stainless steel wires in a four-channel myograph in
which the wires are attached to a force transducer and
micrometer, respectively. The temperature was raised to
37°C, and a gas mixture (composition above) was bubbled in
for the duration of the experiment. Dissection of resistance
arteries from gluteal biopsies and myography protocols were
performed by an operator who was blind to the patient type
(i.e., CHF or CHD).
Myography protocol: ACE and chymase inhibition. Af-
ter a rest period of 30 min, each artery was stretched at
1-min intervals to determine the passive exponential wall
tension-internal circumference (L) relationship. From the
Laplace equation, where P 5 T/r (P is the effective pressure,
T is the wall tension and r is the internal radius), the
equivalent circumference (L100) for a transmural pressure of
100 mm Hg was calculated for each vessel by an iterative
computer method. Each vessel was then set to the normal-
ized internal diameter, L1 5 0.9 3 L100/p, at which
contraction is thought to be optimal (13).
After the above normalization procedure, the arteries
were exposed twice to KPSS (Kreb’s solution with KCl
substituted for NaCl on an equimolar basis) and once to NE
10 mM. After a plateau contraction had been attained with
NE, ACh 3 mM was added to the bath in order to stimulate
endothelium-dependent vasodilation. Vessels that were un-
able to contract to either KPSS or NE, or that showed no
relaxation to ACh (and were, therefore, considered to have
no functionally intact endothelium), were discarded.
Vessels were then incubated for a further 30 min in either
Kreb’s solution alone (vehicle, vessel 1) or with enalaprilat
1026M (vessel 2), chymostatin 1025M (vessel 3) or both
enalaprilat 1026M and chymostatin 1025M (vessel 4),
respectively. Cumulative concentration response (contrac-
tion) curves were then obtained with AI (10211M to 3 3
1026M). After exposure to AI, vessels were washed with
Kreb’s solution to reestablish baseline, and inhibitors were
again added maintaining the same relationship between
vessel and inhibitor. Responses to AI are expressed as the
Abbreviations and Acronyms
ACE 5 angiotensin converting enzyme
ACh 5 acetylcholine
AI 5 angiotensin I
AII 5 angiotensin II
BK 5 bradykinin
CHD 5 coronary heart disease
CHF 5 chronic heart failure
KPSS 5 Kreb’s solution with KCl substituted for NaCl
on an equimolar basis
LV 5 left ventricle, left ventricular
LVEF 5 left ventricular ejection fraction
NE 5 norepinephrine
RAAS 5 renin-angiotensin-aldosterone system
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percent contraction to that elicited by 123 mM KCl (second
exposure) in that vessel.
Responses to BK and ACh. After 30 min, a cumulative
concentration response (contraction) curve was constructed
to NE, then to ACh and finally to BK, with further washes
and incubation periods between curves. Responses to BK
and ACh are expressed as percent change to precontraction
with NE.
Responses to AII. The above protocol was repeated in
arteries from different patients studying the effect of these
inhibitors on cumulative concentration response curves to
AII in place of AI. Responses to AI are expressed as the
percent contraction to that elicited by 123 mM KCl (second
exposure) in that vessel.
Effect of AII type-1 receptor blockade (with losartan).
The effect of losartan (1026M) on the contractile response
to AI was studied in resistance arteries taken from patients
with CHD. The vessels were prepared as described above
but were pre-incubated with losartan rather than enalaprilat
or chymostatin before construction of an AI concentration
response curve.
Statistical analysis. A maximal response was not observed
to AI in arteries in the presence of the combination of
enalaprilat and chymostatin. This prevented calculation of
EC50 (concentration for half-maximum response) or com-
parisons of maximum responses. Instead, the threshold
concentration for the response to AI (defined as the first
concentration at which a response was detected) was iden-
tified for each curve (5). These values were expressed as the
negative logarithm (to ease computation) and entered into a
one-way analysis of variance (ANOVA) with a Bonferroni
correction for multiple comparisons (GraphPad Prism,
GraphPad Software, Inc., San Diego, California). Re-
sponses to BK and ACh were expressed by the pD2
(negative logarithm of the EC50) and maximum response
(% vasodilation). Responses to BK and ACh in vessels 2, 3
and 4 were then compared with vehicle by one-way
ANOVA with a Bonferroni correction for multiple com-
parisons. A similar analysis was performed for responses to
AII. All data in the text are expressed as mean (6 SD), and
all data in graphical form are expressed as mean 6 SE,
unless stated otherwise. Although pD2 values were used
when comparing curves, the equivalent EC50 values (or
threshold concentrations) are stated in the text to ease
comprehension.
RESULTS
Patients. The clinical characteristics of patients taking part
in the study are given in Table 1. Baseline characteristics of
patients with CHD and CHF differed in only two aspects
(except their previously defined differences in LV function
and ACE inhibitor and diuretic prescriptions). First, more
patients with CHF were treated with digoxin, and more
patients with CHD were treated with beta-adrenergic
Table 1. Patient Characteristics
Concentration Response
Curves
Angiotensin I Angiotensin II
CHF CHD CHF CHD
Number 10 10 8 8
Gender (M/F) 8/2 9/1 6/2 7/1
Age (mean [SD]) 70.1 (66.1) 60.3 (67.4) 70.5 (611.1) 66.2 (66.3)
Previous MI 9 2 8 2
Previous CABG 6 1 2 1
NYHA functional class 5 III; 5 II NA 4 II; 4III NA
Hypertension 1 1 2 3
NIDDM 0 0 0 0
Ejection fraction (mean [SD]) 24.5 (66.1) 59.3 (68.4) 21.4 (68.6) 57.9 (69.3)
Drug therapy
ACE inhibitor 10 0 8 0
Diuretic 10 0 8 0
Digoxin 3 0 2 0
Calcium channel blocker 0 2 1 3
Nitrate 4 4 3 4
Beta-blocker 1 9 2 7
HMGCoA reductase inhibitor 5 8 4 5
Aspirin 8 10 4 8
Systolic BP (mean [SD]) 125 (618) 149.2 (69.6) 131 (619) 151 (617)
Diastolic BP (mean [SD]) 70 (69) 82.6 (60.9) 80 (68) 79.5 (62.1)
Glucose (mean [SD]) 5.5 (61.8) 5.9 (61.7) 5.5 (61.0) 5.3 (60.9)
Cholesterol (mean [SD]) 5.0 (60.9) 4.7 (60.8) 4.7 (61.1) 5.0 (61.1)
Creatinine (mean [SD]) 116 (617) 89 (613) 100 (628) 94 (612)
ACE 5 angiotensin converting enzyme; BP 5 blood pressure; CABG 5 coronary artery bypass grafting; CHD 5 coronary heart
disease; CHF 5 chronic heart failure; HMGCoA 5 3-hydroxy-3-methylglutaryl coenzyme A; MI 5 myocardial infarction;
NIDDM 5 noninsulin dependent diabetes mellitus; NYHA 5 New York Heart Association.
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blocking agents. Second, the patients with CHF were older
than the patients with CHD (p 5 0.004).
Characteristics of small resistance arteries from patients
with CHF and CHD. There were no significant differ-
ences between the normalized diameters of the arteries from
the different patient groups. Similarly, there were no differ-
ences in contractile responsiveness or endothelium-
dependent vasodilator responsiveness to KPSS, NE and
ACh, respectively, between experimental groups (unpaired t
test).
AI concentration response curves: effect of enalaprilat
and chymostatin. CHF. Responses to AI in arteries from
patients with CHF are shown in Figure 1. Angiotensin I
induced a dose-dependent contraction in subcutaneous
resistance arteries from CHF patients (n 5 6) with a
threshold concentration of 5.03 (3.82) 3 10210M and a
maximum at 0.1 mM in the absence of inhibitors. In the
presence of enalaprilat (n 5 6), the threshold concentration
for AI was 2.44 (3.86) 3 1028M, representing a fifty-fold
increase compared with control. In the presence of chymo-
statin (n 5 6), the threshold was 0.56 (1.20) 3 1028M.
However, in the presence of the combination of enalaprilat
and chymostatin (n 5 8), the threshold was 0.77 (1.07) 3
1026M, representing a 1,500-fold increase compared with
control. Thus, enalaprilat alone induced a significant shift to
the right of the dose-response curve to AI (p , 0.05), but
no inhibition was observed with chymostatin alone (p .
0.05) compared with vehicle. The combination of enalapri-
lat and chymostatin significantly inhibited the response to
AI (p , 0.001) compared with vehicle. The shift to the
right of the dose-response curve observed in the presence of
the combination of enalaprilat and chymostatin was signif-
icantly greater than that obtained with enalaprilat alone
(p , 0.01).
CHD. Responses to AI in arteries from patients with CHD
are shown in Figure 2. Angiotensin I induced a dose-
dependent contraction in subcutaneous resistance arteries
from patients with CHD (group 1, n 5 6) with a threshold
concentration of 2.76 (3.36) 3 1029M and a maximum
response at 0.1 mM in the absence of any inhibitors. The
thresholds in the presence of enalaprilat (n 5 6), chymo-
Figure 1. Response to AI (10211M to 3 3 1026M) in arteries from patients with CHF in the presence of vehicle, enalaprilat, chymostatin or both
chymostatin and enalaprilat. AI 5 angiotensin I; CHF 5 chronic heart failure; KPSS 5 Kreb’s solution with KCl substituted for NaCl on an equimolar
basis.
Figure 2. Response to AI (10211M to 3 3 1026M) in arteries from patients with CHD in the presence of vehicle, enalaprilat, chymostatin or both
chymostatin and enalaprilat. AI 5 angiotensin I; CHD 5 coronary heart disease. KPSS 5 Kreb’s solution with KCl substituted for NaCl on an equimolar
basis.
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statin (n 5 6) and combination (n 5 8) were, respectively,
2.20 (3.85) 3 1028M, 1.32 (1.33) 3 1029M and 2.90
(2.70) 3 1027M. Thus, no inhibition was observed in the
presence of chymostatin alone (p . 0.05) compared with
vehicle. In contrast with the response in vessels from CHF,
no inhibition of the response to AI was observed in the
presence of enalaprilat alone (p . 0.05) compared with
vehicle. However, there was a very significant shift in the
dose-response curve to the right when enalaprilat and
chymostatin were combined (p , 0.001).
BK concentration response curves. In the arteries of
patients with CHF, neither enalaprilat, chymostatin or the
combination changed the maximum response to BK (p .
0.05). However, there was a trend toward potentiation of
the response to BK in the presence of enalaprilat alone and
enalaprilat in combination with chymostatin (Table 2). This
did not reach significance (p . 0.05).
A similar situation was observed in the arteries of patients
with CHD. Thus, there was a trend toward potentiation in
the presence of both enalaprilat and the combination of
enalaprilat and chymostatin (Table 2). Again, this did not
reach significance. There was no change in the maximum
response to BK in the presence of any inhibitor.
ACh concentration response curves. There was no effect
of either inhibitor, alone or in combination, on responses to
ACh in arteries of patients with CHF and CHD. No
difference was observed between the response to ACh in the
absence of inhibitors in arteries from patients with CHF
compared with those from patients with CHD.
AII concentration response curves. No significant inhi-
bition of the AII response was observed with either inhib-
itor alone, or in combination, in arteries from patients with
CHF and CHD (data not shown).
Study of the effect of AII receptor blockade on responses
to AI. In the presence of losartan, the response of subcu-
taneous resistance arteries to AI was completely abolished
(n 5 7, data not shown).
DISCUSSION
In this study we have been able to confirm that a non-ACE
pathway that generates AI from AII exists in human small
subcutaneous resistance arteries. Our findings support those
of Voors et al. (5) in internal mammary arteries taken from
patients with CHD and also extend our previous findings in
small resistance arteries from healthy volunteers to patients
with CHD (6). More importantly, however, we now report
on patients with CHF receiving long-term treatment with
ACE inhibitors—a group in whom intense and persistent
blockade of the renin-angiotensin system is thought to be
therapeutically desirable.
Our findings in small resistance arteries from patients
with CHD are qualitatively very similar to our earlier
observations in younger healthy subjects. Collectively, the
available data in healthy volunteers and patients with CHD
show that neither an ACE inhibitor alone, nor a chymase
inhibitor alone, substantially inhibits the conversion of AI
to AII in small arteries, medium-sized arteries or veins (5,6).
Only the combination of an ACE inhibitor and a chymase
inhibitor effectively blocks AI to AII conversion. These
findings imply that both the limbs of the dual pathway for
conversion of AI to AII have a high capacity and that
substrate can normally be rapidly and completely shunted
through one limb, should the other be blocked.
Responses to AII, BK and ACh. It is important to note
that the response of small resistance vessels to AII was not
affected by enalaprilat, chymostatin or the combination of
the two. Thus, there is no evidence that potentiation of the
action of vasodilator substances by any of these inhibitors
indirectly influences the response to AI. We have previously
demonstrated that enalaprilat potentiates the response to
BK in resistance arteries from normal subjects (6). In these
studies we were able to confirm that, in both CHF and
CHD subjects, there was a trend toward potentiation of the
dilator response to BK in the presence of enalaprilat—
confirming that ACE is involved in the degradation of this
peptide and that enalaprilat can inhibit this. There was no
evidence that chymostatin had any effect on responses to
BK.
We also showed that vessels from patients with CHF and
CHD exhibited a vasodilator response to ACh. There was
no apparent difference between the patient groups, suggest-
ing that endothelial function in CHF does not differ from
CHD. However, in the absence of a normal control group,
it is not possible to make any inference about vascular
endothelial function in these patients with cardiovascular
disease compared with healthy subjects. Our results do raise
the possibility that previous reports of endothelial dysfunc-
Table 2. EC50 and Maximum Responses to Bradykinin in Arteries from CHF and CHD
CHD CHF
EC50
Max
(% resp NE) EC50
Max
(% resp NE)
Vehicle 1.99 (0.33) 3 1027 96.9 (7.0) 1.78 (0.23) 3 1027 92.6 (7.0)
Enalaprilat 3.08 (0.12) 3 1028 84.8 (14.0) 4.0 (0.12) 3 1028 95.3 (5.0)
Chymostatin 3.09 (0.13) 3 1027 89.2 (5.0) 1.20 (0.32) 3 1027 94.4 (7.0)
Combination 5.25 (0.254) 3 1028 88.6 (15.0) 5.57 (0.13) 3 1028 94.4 (6.0)
No significant difference was found in the maximum responses or EC50s between control and each experimental group in either
CHF or CHD patients (p . 0.05 by ANOVA).
CHD 5 coronary heart disease; CHF 5 chronic heart failure; NE 5 norepinephrine.
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tion in CHF may, in fact, reflect endothelial dysfunction in
CHD rather than in CHF per se.
Responses to AI in arteries from patients with CHF and
CHD. In contrast with the responses seen in arteries from
CHD patients, the response to AI in arteries from patients
with CHF proved to be quite different. Contrary to our
original expectation, we did not find “up-regulation” of the
chymostatin-sensitive pathway in these subjects and instead
found that the small resistance arteries from these patients
were more sensitive to ACE inhibition than those from
healthy volunteers or patients with CHD. It is unlikely that
this finding is due to the minor age and therapy differences
between CHF and CHD patients. There are, however, at
least two potential explanations.
The first possibility is that the chymostatin-sensitive
non-ACE pathway is actually down-regulated in patients
with CHF treated with an ACE inhibitor. Why this should
occur is not clear, though it could occur if the ACE pathway
is up-regulated. The second possibility, that ACE activity is
induced, could also explain our findings in CHF, and it is
known that both CHF and ACE inhibitor treatment,
experimentally, can induce ACE. Even if this were the case,
however, AI should be diverted through the alternative limb
of the dual pathway when an ACE inhibitor is present. Our
findings, therefore, imply that the chymase pathway is
down-regulated alone or in conjunction with induction of
ACE in CHF.
Our findings differ from those obtained by Wolny et al.
(14) who studied the responses to AI in coronary arteries
from patients with CHF treated with ACE inhibitors. In
these vessels, cilazaprilat was unable to inhibit the response
to AI; but chymostatin inhibited it by 78%, and the
combination of chymostatin and cilazaprilat inhibited the
response by 97%. Thus, it would appear that, in coronary
arteries, the chymase pathway is predominant though the
incremental inhibition obtained by combining chymostatin
and cilazaprilat suggests that some of the conversion of AI
to AII is mediated by ACE. It is possible that the results
obtained by Wolny et al. reflect a difference in the physiol-
ogy of coronary arteries compared with resistance arteries. It
is possible that the relative contribution of ACE and
chymase to AII generation varies between subcutaneous
resistance arteries and coronary arteries. Furthermore, the
effect of the inhibitors was only studied at 1 mM AI, which
is supraphysiological, and not over a whole concentration
range. It is, therefore, difficult to make a direct comparison
between their results and ours.
Study limitations. One limitation of our study is that we
are not able to distinguish between the effect of ACE
inhibition and the presence of CHF on our findings. This
question could be resolved in two ways: one approach might
be to study arteries obtained from ACE inhibitor naive
patients with CHF and a second would be to study arteries
from patients with CHD before and after ACE-inhibition.
Despite this limitation, however, we feel that our findings
are important since they suggest that physiological escape
from ACE inhibition can occur in a relevant clinical
situation.
Conclusions. Even though the chymase pathway may be
less active in CHF, we did find an incremental and
statistically significant inhibition of AI to AII conversion
with the combination of chymostatin and enalaprilat com-
pared with enalaprilat alone in these patients. This finding
provides a rationale for using drugs that inhibit the action of
AII directly in the treatment of patients with CHD and
CHF; an alternative, and potentially worthwhile approach,
would be the development of agents that inhibit non-ACE
AII generating pathways.
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